Case Study:
Helping a leader in menopause care to improve equity of access and choice of HRT products in the UK
The Client
Our client is a leader in the development and supply of women’s health medicines and they commissioned Triducive to help address the inequity of choice and access to HRT options and the inconsistent system of menopause management.
Therapy Area
In recent years there have been publications/statements from leading bodies establishing transdermal therapy with good VTE safety compared to oral therapy. However, at the time, the majority of UK formularies listed transdermal patches as a second-line option to oral options. Whilst this was historically due to cost, habit and routine there is the rationale for transdermal options to be offered to patients as an equal first-line choice.
Opportunity
With a diverse and growing population of women reaching and living well beyond the menopause, the impact of this inequity is becoming more pronounced. The objective of this project was to establish a consensus that supports a greater equity of access and choice of HRT and provision of individualised care.
Our client identified the opportunity to address:
Inequity of choice and access to HRT options
An inconsistent system of menopause management across the UK
Approach
Triducive began working on this project mid 2021 and together with the client team, designed a modified Delphi approach which aimed to create: